other material
confidence high
sentiment negative
materiality 0.60
BriaPro subsidiary reports 9-month net loss of $712K; going concern uncertainty
BriaCell Therapeutics Corp.
- Net loss for 9 months ended April 30, 2026: $712,236, vs $519,804 in prior-year period.
- Accumulated deficit of $1,892,661; cash $299,950 vs $1 at July 31, 2025.
- Acquired sCD80 license from parent BriaCell for 23,972,589 shares valued at $846,532.
- Due to related parties (BriaCell) $2,093,345; going concern depends on parent financing.
- R&D expenses $649,991; granted 7,189,000 RSUs to directors on April 1, 2026.